Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 53 entries
Sorted by: Best Match Show Resources per page
[Not Available].

Duodecim; laaketieteellinen aikakauskirja

Nieminen U, Färkkilä M, Lassila R.
PMID: 17615811
Duodecim. 2007;123(10):1191.

No abstract available.

Cite
Nieminen U, Färkkilä M, Lassila R. Verenvuototautipotilaiden C-hepatiitin parantuneet hoitotulokset. [Not Available]. Duodecim. 2007;123(10):1191
Nieminen, U., Färkkilä, M., & Lassila, R. (2007). Verenvuototautipotilaiden C-hepatiitin parantuneet hoitotulokset. [Not Available]. Duodecim; laaketieteellinen aikakauskirja, 123(10), 1191.
Nieminen, Urpo, et al. "Verenvuototautipotilaiden C-hepatiitin parantuneet hoitotulokset." [Not Available]. Duodecim; laaketieteellinen aikakauskirja vol. 123,10 (2007): 1191.
Nieminen U, Färkkilä M, Lassila R. Verenvuototautipotilaiden C-hepatiitin parantuneet hoitotulokset. [Not Available]. Duodecim. 2007;123(10):1191. Finnish. PMID: 17615811.
Copy Download .nbib Format: NLM
In Crohn's Disease, Anti-TNF-α Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells.

ISRN gastroenterology

Hölttä V, Sipponen T, Westerholm-Ormio M, Salo HM, Kolho KL, Färkkilä M, Savilahti E, Vaarala O, Klemetti P.
PMID: 22778976
ISRN Gastroenterol. 2012;2012:505432. doi: 10.5402/2012/505432. Epub 2012 Jun 14.

Aim. In Crohn's disease (CD), anti-TNF-α treatment is a potent medication. We aimed to characterize the effect of anti-TNF-α treatment on T effector and regulatory cells. Material and Methods. We studied T-effector and regulatory cells on cellular and mRNA...

Cite
Hölttä V, Sipponen T, Westerholm-Ormio M, et al. In Crohn's Disease, Anti-TNF-α Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells. ISRN Gastroenterol. 2012;2012:505432doi: 10.5402/2012/505432.
Hölttä, V., Sipponen, T., Westerholm-Ormio, M., Salo, H. M., Kolho, K. L., Färkkilä, M., Savilahti, E., Vaarala, O., & Klemetti, P. (2012). In Crohn's Disease, Anti-TNF-α Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells. ISRN gastroenterology, 2012505432. https://doi.org/10.5402/2012/505432
Hölttä, Veera, et al. "In Crohn's Disease, Anti-TNF-α Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells." ISRN gastroenterology vol. 2012 (2012): 505432. doi: https://doi.org/10.5402/2012/505432
Hölttä V, Sipponen T, Westerholm-Ormio M, Salo HM, Kolho KL, Färkkilä M, Savilahti E, Vaarala O, Klemetti P. In Crohn's Disease, Anti-TNF-α Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells. ISRN Gastroenterol. 2012;2012:505432. doi: 10.5402/2012/505432. Epub 2012 Jun 14. PMID: 22778976; PMCID: PMC3384926.
Copy Download .nbib Format: NLM
The Fanconi Anemia Pathway in Cancer.

Annual review of cancer biology

Niraj J, Färkkilä A, D'Andrea AD.
PMID: 30882047
Annu Rev Cancer Biol. 2019 Mar;3:457-478. doi: 10.1146/annurev-cancerbio-030617-050422. Epub 2018 Dec 03.

Fanconi anemia (FA) is a complex genetic disorder characterized by bone marrow failure (BMF), congenital defects, inability to repair DNA interstrand cross-links (ICLs), and cancer predisposition. FA presents two seemingly opposite characteristics: (

Cite
Niraj J, Färkkilä A, D'Andrea AD. The Fanconi Anemia Pathway in Cancer. Annu Rev Cancer Biol. 2018;3:457-478doi: 10.1146/annurev-cancerbio-030617-050422.
Niraj, J., Färkkilä, A., & D'Andrea, A. D. (2019). The Fanconi Anemia Pathway in Cancer. Annual review of cancer biology, 3457-478. https://doi.org/10.1146/annurev-cancerbio-030617-050422
Niraj, Joshi, et al. "The Fanconi Anemia Pathway in Cancer." Annual review of cancer biology vol. 3 (2019): 457-478. doi: https://doi.org/10.1146/annurev-cancerbio-030617-050422
Niraj J, Färkkilä A, D'Andrea AD. The Fanconi Anemia Pathway in Cancer. Annu Rev Cancer Biol. 2019 Mar;3:457-478. doi: 10.1146/annurev-cancerbio-030617-050422. Epub 2018 Dec 03. PMID: 30882047; PMCID: PMC6417835.
Copy Download .nbib Format: NLM
Rapidly growing and ulcerating metastatic renal cell carcinoma of the lower lip: A case report and review of the literature.

Oncology letters

Suojanen J, Färkkilä E, Helkamaa T, Loimu V, Törnwall J, Lindqvist C, Hagström J, Mesimäki K.
PMID: 25289097
Oncol Lett. 2014 Nov;8(5):2175-2178. doi: 10.3892/ol.2014.2505. Epub 2014 Sep 05.

Renal cell carcinomas (RCCs) have a tendency to metastasize at an early stage, therefore, the patients frequently exhibit metastatic disease at the time of diagnosis. Common locations for the metastases are adjacent organs and abdominal lymph nodes; however, occasionally...

Cite
Suojanen J, Färkkilä E, Helkamaa T, et al. Rapidly growing and ulcerating metastatic renal cell carcinoma of the lower lip: A case report and review of the literature. Oncol Lett. 2014;8(5):2175-2178doi: 10.3892/ol.2014.2505.
Suojanen, J., Färkkilä, E., Helkamaa, T., Loimu, V., Törnwall, J., Lindqvist, C., Hagström, J., & Mesimäki, K. (2014). Rapidly growing and ulcerating metastatic renal cell carcinoma of the lower lip: A case report and review of the literature. Oncology letters, 8(5), 2175-2178. https://doi.org/10.3892/ol.2014.2505
Suojanen, Juho, et al. "Rapidly growing and ulcerating metastatic renal cell carcinoma of the lower lip: A case report and review of the literature." Oncology letters vol. 8,5 (2014): 2175-2178. doi: https://doi.org/10.3892/ol.2014.2505
Suojanen J, Färkkilä E, Helkamaa T, Loimu V, Törnwall J, Lindqvist C, Hagström J, Mesimäki K. Rapidly growing and ulcerating metastatic renal cell carcinoma of the lower lip: A case report and review of the literature. Oncol Lett. 2014 Nov;8(5):2175-2178. doi: 10.3892/ol.2014.2505. Epub 2014 Sep 05. PMID: 25289097; PMCID: PMC4186528.
Copy Download .nbib Format: NLM
Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland.

United European gastroenterology journal

Barner-Rasmussen N, Pukkala E, Hadkhale K, Färkkilä M.
PMID: 34533900
United European Gastroenterol J. 2021 Dec;9(10):1128-1135. doi: 10.1002/ueg2.12154. Epub 2021 Sep 17.

BACKGROUND: Cholangiocarcinoma (CCA) is a cancer arising from the intra- and extrahepatic bile ducts. The early stages are often asymptomatic, CCA is frequently diagnosed in an advanced stage and the prognosis of CCA is often dismal.OBJECTIVE: Our objective was...

Cite
Barner-Rasmussen N, Pukkala E, Hadkhale K, et al. Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland. United European Gastroenterol J. 2021;9(10):1128-1135doi: 10.1002/ueg2.12154.
Barner-Rasmussen, N., Pukkala, E., Hadkhale, K., & Färkkilä, M. (2021). Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland. United European gastroenterology journal, 9(10), 1128-1135. https://doi.org/10.1002/ueg2.12154
Barner-Rasmussen, Nina, et al. "Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland." United European gastroenterology journal vol. 9,10 (2021): 1128-1135. doi: https://doi.org/10.1002/ueg2.12154
Barner-Rasmussen N, Pukkala E, Hadkhale K, Färkkilä M. Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland. United European Gastroenterol J. 2021 Dec;9(10):1128-1135. doi: 10.1002/ueg2.12154. Epub 2021 Sep 17. PMID: 34533900.
Copy Download .nbib Format: NLM
REPLY.

Hepatology (Baltimore, Md.)

Åberg F, Färkkilä M, Salomaa V, Jula A.
PMID: 31788830
Hepatology. 2020 May;71(5):1888-1889. doi: 10.1002/hep.31051.

No abstract available.

Cite
Åberg F, Färkkilä M, Salomaa V, et al. REPLY. Hepatology. 2020;71(5):1888-1889doi: 10.1002/hep.31051.
Åberg, F., Färkkilä, M., Salomaa, V., & Jula, A. (2020). REPLY. Hepatology (Baltimore, Md.), 71(5), 1888-1889. https://doi.org/10.1002/hep.31051
Åberg, Fredrik, et al. "REPLY." Hepatology (Baltimore, Md.) vol. 71,5 (2020): 1888-1889. doi: https://doi.org/10.1002/hep.31051
Åberg F, Färkkilä M, Salomaa V, Jula A. REPLY. Hepatology. 2020 May;71(5):1888-1889. doi: 10.1002/hep.31051. PMID: 31788830.
Copy Download .nbib Format: NLM
Executive Functions and Emotion-Attention Interaction in Assessment of Brain Health: Reliability of Repeated Testing With Executive RT Test and Correlation With BRIEF-A Questionnaire.

Frontiers in psychology

Erkkilä M, Peräkylä J, Hartikainen KM.
PMID: 30618977
Front Psychol. 2018 Dec 11;9:2556. doi: 10.3389/fpsyg.2018.02556. eCollection 2018.

Executive functions (EF) rely on intact fronto-subcortical networks. An insult, disorder or treatment compromising brain health may impair the functioning of these widespread networks and consequently disrupt EF. Changes in brain health due to treatment or disorder can be...

Cite
Erkkilä M, Peräkylä J, Hartikainen KM. Executive Functions and Emotion-Attention Interaction in Assessment of Brain Health: Reliability of Repeated Testing With Executive RT Test and Correlation With BRIEF-A Questionnaire. Front Psychol. 2018;9:2556doi: 10.3389/fpsyg.2018.02556.
Erkkilä, M., Peräkylä, J., & Hartikainen, K. M. (2018). Executive Functions and Emotion-Attention Interaction in Assessment of Brain Health: Reliability of Repeated Testing With Executive RT Test and Correlation With BRIEF-A Questionnaire. Frontiers in psychology, 92556. https://doi.org/10.3389/fpsyg.2018.02556
Erkkilä, Mikko, et al. "Executive Functions and Emotion-Attention Interaction in Assessment of Brain Health: Reliability of Repeated Testing With Executive RT Test and Correlation With BRIEF-A Questionnaire." Frontiers in psychology vol. 9 (2018): 2556. doi: https://doi.org/10.3389/fpsyg.2018.02556
Erkkilä M, Peräkylä J, Hartikainen KM. Executive Functions and Emotion-Attention Interaction in Assessment of Brain Health: Reliability of Repeated Testing With Executive RT Test and Correlation With BRIEF-A Questionnaire. Front Psychol. 2018 Dec 11;9:2556. doi: 10.3389/fpsyg.2018.02556. eCollection 2018. PMID: 30618977; PMCID: PMC6297677.
Copy Download .nbib Format: NLM
Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile.

Hepatology (Baltimore, Md.)

Vedeld HM, Grimsrud MM, Andresen K, Pharo HD, von Seth E, Karlsen TH, Honne H, Paulsen V, Färkkilä MA, Bergquist A, Jeanmougin M, Aabakken L, Boberg KM, Folseraas T, Lind GE.
PMID: 34435693
Hepatology. 2021 Aug 26; doi: 10.1002/hep.32125. Epub 2021 Aug 26.

BACKGROUND AND AIMS: Primary sclerosing cholangitis (PSC) is associated with increased risk of cholangiocarcinoma (CCA). Early and accurate CCA detection represents an unmet clinical need as the majority of patients with PSC are diagnosed at an advanced stage of...

Cite
Vedeld HM, Grimsrud MM, Andresen K, et al. Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile. Hepatology. 2021;doi: 10.1002/hep.32125.
Vedeld, H. M., Grimsrud, M. M., Andresen, K., Pharo, H. D., von Seth, E., Karlsen, T. H., Honne, H., Paulsen, V., Färkkilä, M. A., Bergquist, A., Jeanmougin, M., Aabakken, L., Boberg, K. M., Folseraas, T., & Lind, G. E. (2021). Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile. Hepatology (Baltimore, Md.), . https://doi.org/10.1002/hep.32125
Vedeld, Hege Marie, et al. "Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile." Hepatology (Baltimore, Md.) vol. (2021). doi: https://doi.org/10.1002/hep.32125
Vedeld HM, Grimsrud MM, Andresen K, Pharo HD, von Seth E, Karlsen TH, Honne H, Paulsen V, Färkkilä MA, Bergquist A, Jeanmougin M, Aabakken L, Boberg KM, Folseraas T, Lind GE. Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile. Hepatology. 2021 Aug 26; doi: 10.1002/hep.32125. Epub 2021 Aug 26. PMID: 34435693.
Copy Download .nbib Format: NLM
Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis.

United European gastroenterology journal

Tenca A, Färkkilä M, Arola J, Jaakkola T, Penagini R, Kolho KL.
PMID: 27536366
United European Gastroenterol J. 2016 Aug;4(4):562-9. doi: 10.1177/2050640615616012. Epub 2015 Oct 30.

BACKGROUND: The natural history of pediatric-onset primary sclerosing cholangitis (PSC) and overlap with autoimmune hepatitis (PSC/AIH) is poorly known.OBJECTIVE: The aim of this study was to evaluate the clinical outcome of patients with pediatric-onset disease in a tertiary referral...

Cite
Tenca A, Färkkilä M, Arola J, et al. Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis. United European Gastroenterol J. 2015;4(4):562-9doi: 10.1177/2050640615616012.
Tenca, A., Färkkilä, M., Arola, J., Jaakkola, T., Penagini, R., & Kolho, K. L. (2016). Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis. United European gastroenterology journal, 4(4), 562-9. https://doi.org/10.1177/2050640615616012
Tenca, Andrea, et al. "Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis." United European gastroenterology journal vol. 4,4 (2016): 562-9. doi: https://doi.org/10.1177/2050640615616012
Tenca A, Färkkilä M, Arola J, Jaakkola T, Penagini R, Kolho KL. Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis. United European Gastroenterol J. 2016 Aug;4(4):562-9. doi: 10.1177/2050640615616012. Epub 2015 Oct 30. PMID: 27536366; PMCID: PMC4971785.
Copy Download .nbib Format: NLM
Correction: TERT promoter mutation in adult granulosa cell tumor of the ovary.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Pilsworth JA, Cochrane DR, Xia Z, Aubert G, Färkkilä AEM, Horlings HM, Yanagida S, Yang W, Lim JLP, Wang YK, Bashashati A, Keul J, Wong A, Norris K, Brucker SY, Taran FA, Krämer B, Staebler A, van Meurs H, Oliva E, Shah SP, Kommoss S, Kommoss F, Gilks CB, Baird DM, Huntsman DG.
PMID: 29968850
Mod Pathol. 2019 Apr;32(4):593. doi: 10.1038/s41379-018-0085-8.

The original version of this Article omitted the author Hannah van Meurs from the Department of Gynecology, Center for Gynecologic Oncology Amsterdam, Academic Medical Center, 1100 DD Amsterdam, The Netherlands. This has been corrected in both the PDF and...

Cite
Pilsworth JA, Cochrane DR, Xia Z, et al. Correction: TERT promoter mutation in adult granulosa cell tumor of the ovary. Mod Pathol. 2019;32(4):593doi: 10.1038/s41379-018-0085-8.
Pilsworth, J. A., Cochrane, D. R., Xia, Z., Aubert, G., Färkkilä, A. E. M., Horlings, H. M., Yanagida, S., Yang, W., Lim, J. L. P., Wang, Y. K., Bashashati, A., Keul, J., Wong, A., Norris, K., Brucker, S. Y., Taran, F. A., Krämer, B., Staebler, A., van Meurs, H., Oliva, E., Shah, S. P., Kommoss, S., Kommoss, F., Gilks, C. B., Baird, D. M., & Huntsman, D. G. (2019). Correction: TERT promoter mutation in adult granulosa cell tumor of the ovary. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 32(4), 593. https://doi.org/10.1038/s41379-018-0085-8
Pilsworth, Jessica A, et al. "Correction: TERT promoter mutation in adult granulosa cell tumor of the ovary." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc vol. 32,4 (2019): 593. doi: https://doi.org/10.1038/s41379-018-0085-8
Pilsworth JA, Cochrane DR, Xia Z, Aubert G, Färkkilä AEM, Horlings HM, Yanagida S, Yang W, Lim JLP, Wang YK, Bashashati A, Keul J, Wong A, Norris K, Brucker SY, Taran FA, Krämer B, Staebler A, van Meurs H, Oliva E, Shah SP, Kommoss S, Kommoss F, Gilks CB, Baird DM, Huntsman DG. Correction: TERT promoter mutation in adult granulosa cell tumor of the ovary. Mod Pathol. 2019 Apr;32(4):593. doi: 10.1038/s41379-018-0085-8. PMID: 29968850.
Copy Download .nbib Format: NLM
Incidence and Mortality in Upper Gastrointestinal Cancer After Negative Endoscopy for Gastroesophageal Reflux Disease.

Gastroenterology

Holmberg D, Santoni G, von Euler-Chelpin MC, Färkkilä M, Kauppila JH, Maret-Ouda J, Ness-Jensen E, Lagergren J.
PMID: 34627859
Gastroenterology. 2021 Oct 08; doi: 10.1053/j.gastro.2021.10.003. Epub 2021 Oct 08.

BACKGROUND AND AIMS: Gastroesophageal reflux disease (GERD) is associated with an increased risk of cancer of the upper gastrointestinal tract. This study aimed to assess whether and to what extent a negative upper endoscopy in patients with GERD is...

Cite
Holmberg D, Santoni G, von Euler-Chelpin MC, et al. Incidence and Mortality in Upper Gastrointestinal Cancer After Negative Endoscopy for Gastroesophageal Reflux Disease. Gastroenterology. 2021;doi: 10.1053/j.gastro.2021.10.003.
Holmberg, D., Santoni, G., von Euler-Chelpin, M. C., Färkkilä, M., Kauppila, J. H., Maret-Ouda, J., Ness-Jensen, E., & Lagergren, J. (2021). Incidence and Mortality in Upper Gastrointestinal Cancer After Negative Endoscopy for Gastroesophageal Reflux Disease. Gastroenterology, . https://doi.org/10.1053/j.gastro.2021.10.003
Holmberg, Dag, et al. "Incidence and Mortality in Upper Gastrointestinal Cancer After Negative Endoscopy for Gastroesophageal Reflux Disease." Gastroenterology vol. (2021). doi: https://doi.org/10.1053/j.gastro.2021.10.003
Holmberg D, Santoni G, von Euler-Chelpin MC, Färkkilä M, Kauppila JH, Maret-Ouda J, Ness-Jensen E, Lagergren J. Incidence and Mortality in Upper Gastrointestinal Cancer After Negative Endoscopy for Gastroesophageal Reflux Disease. Gastroenterology. 2021 Oct 08; doi: 10.1053/j.gastro.2021.10.003. Epub 2021 Oct 08. PMID: 34627859.
Copy Download .nbib Format: NLM
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.

Cancer cell

Duraiswamy J, Turrini R, Minasyan A, Barras D, Crespo I, Grimm AJ, Casado J, Genolet R, Benedetti F, Wicky A, Ioannidou K, Castro W, Neal C, Moriot A, Renaud-Tissot S, Anstett V, Fahr N, Tanyi JL, Eiva MA, Jacobson CA, Montone KT, Westergaard MCW, Svane IM, Kandalaft LE, Delorenzi M, Sorger PK, Färkkilä A, Michielin O, Zoete V, Carmona SJ, Foukas PG, Powell DJ, Rusakiewicz S, Doucey MA, Dangaj Laniti D, Coukos G.
PMID: 34739845
Cancer Cell. 2021 Dec 13;39(12):1623-1642.e20. doi: 10.1016/j.ccell.2021.10.008. Epub 2021 Nov 04.

The mechanisms regulating exhaustion of tumor-infiltrating lymphocytes (TIL) and responsiveness to PD-1 blockade remain partly unknown. In human ovarian cancer, we show that tumor-specific CD8

Cite
Duraiswamy J, Turrini R, Minasyan A, et al. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell. 2021;39(12):1623-1642.e20doi: 10.1016/j.ccell.2021.10.008.
Duraiswamy, J., Turrini, R., Minasyan, A., Barras, D., Crespo, I., Grimm, A. J., Casado, J., Genolet, R., Benedetti, F., Wicky, A., Ioannidou, K., Castro, W., Neal, C., Moriot, A., Renaud-Tissot, S., Anstett, V., Fahr, N., Tanyi, J. L., Eiva, M. A., Jacobson, C. A., Montone, K. T., Westergaard, M. C. W., Svane, I. M., Kandalaft, L. E., Delorenzi, M., Sorger, P. K., Färkkilä, A., Michielin, O., Zoete, V., Carmona, S. J., Foukas, P. G., Powell, D. J., Rusakiewicz, S., Doucey, M. A., Dangaj Laniti, D., & Coukos, G. (2021). Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer cell, 39(12), 1623-1642.e20. https://doi.org/10.1016/j.ccell.2021.10.008
Duraiswamy, Jaikumar, et al. "Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation." Cancer cell vol. 39,12 (2021): 1623-1642.e20. doi: https://doi.org/10.1016/j.ccell.2021.10.008
Duraiswamy J, Turrini R, Minasyan A, Barras D, Crespo I, Grimm AJ, Casado J, Genolet R, Benedetti F, Wicky A, Ioannidou K, Castro W, Neal C, Moriot A, Renaud-Tissot S, Anstett V, Fahr N, Tanyi JL, Eiva MA, Jacobson CA, Montone KT, Westergaard MCW, Svane IM, Kandalaft LE, Delorenzi M, Sorger PK, Färkkilä A, Michielin O, Zoete V, Carmona SJ, Foukas PG, Powell DJ, Rusakiewicz S, Doucey MA, Dangaj Laniti D, Coukos G. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell. 2021 Dec 13;39(12):1623-1642.e20. doi: 10.1016/j.ccell.2021.10.008. Epub 2021 Nov 04. PMID: 34739845.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 53 entries